CXCR2 antagonism was tested in combination with immunotherapy consisting of adenovirus encoded TNF-related apoptosis ligand (TRAIL) plus TLR9 agonist, CpG, oligonucleotide (AdT + CpG) in a murine model of breast cancer. The gene discussed is CXCR2; the disease is breast cancer.